Peer reviewed

Continued treatment with tirzepatide for maintenance of weight reduction

SURMOUNT-4 randomized withdrawal trial evaluating continued tirzepatide treatment versus placebo.

JAMAPublished 2023-12-11Accessed 2026-07-12

Open original source

Registry record

Source metadata

Publisher: JAMA
Source type: Peer reviewed
Registry ID: jama-surmount4-withdrawal-2023

Source usage

Linked from 2 pages

Video audit

Retatrutide Masterclass: How To Use It Optimally (Dose, Frequency, Diet, Exercise, & Supplements)

Video audit

Mounjaro (tirzepatide): The newest diabetes and obesity medication

Interpretation boundary

What this record can and cannot establish

Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.